e-learning
resources
Virtual 2020
Pre-Congress Content
Pharmacological management of COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Influence of vaccine prevention of pneumoccocus conjugated vaccine on mortality in patients with COPD
V. Antonov (Chelyabinsk (Chelyabinsk Oblast), Russian Federation), G. Ignatova (Chelyabinsk (Chelyabinsk Oblast), Russian Federation)
Source:
Virtual Congress 2020 – Pharmacological management of COPD
Session:
Pharmacological management of COPD
Session type:
E-poster session
Number:
2425
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
V. Antonov (Chelyabinsk (Chelyabinsk Oblast), Russian Federation), G. Ignatova (Chelyabinsk (Chelyabinsk Oblast), Russian Federation). Influence of vaccine prevention of pneumoccocus conjugated vaccine on mortality in patients with COPD. 2425
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Effects of pneumococcal vaccine in patients with chronic respiratory disease
Source: Annual Congress 2007 - Different aspects of COPD exacerbations
Year: 2007
Effects of pneumococcal vaccine in patients with chronic respiratory disease
Source: Eur Respir Rev 2008; 17: 43-45
Year: 2008
Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects
Source: Eur Respir J 2005; 26: 1086-1091
Year: 2005
Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly
Source: Eur Respir J 2010; 36: 608-614
Year: 2010
Additive preventive effect of influenza and pneumococcal vaccines in elderly persons
Source: Eur Respir J 2004; 23: 363-368
Year: 2004
Efficacy of influenza and pneumococcal vaccinations among patients with COPD
Source: Annual Congress 2007 - Treatment of COPD
Year: 2007
Effectiveness data on prevention of COPD exacerbations with 13-valent pneumococal conjugate vaccine (PCV13)
Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis
Year: 2017
No preventive effects of 23-valent pneumococcal polysaccharide vaccine in patients with chronic renal failure
Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment
Year: 2016
Real-life effectiveness data on prevention OF COPD and asthma exacerbations with 13-valent pneumococcal conjugate vaccine (PCV13)
Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections
Year: 2016
Aetiology of paediatric pneumonia after the introduction of pneumococcal conjugate vaccine
Source: Eur Respir J 2013; 42: 1595-1603
Year: 2013
Analysis of the Effect of pneumococcal vaccination in patients with COPD in combination with bronchiectasis
Source: Virtual Congress 2021 – Bronchiectasis and pleural infection
Year: 2021
Vaccination of COPD patients with a pneumococcus type 6B tetanus toxoid conjugate vaccine
Source: Eur Respir J 2002; 20: 813-818
Year: 2002
Societal perspective and challenges of influenza and pneumococcal vaccination in patients at risk of respiratory complications
Source: Annual Congress 2008 - Why vaccinate patients with chronic respiratory conditions? Today and tomorrow's perspectives
Year: 2008
Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands
Source: Eur Respir J 2015; 46: 1407-1416
Year: 2015
Previous pneumococcal polysaccharide vaccine impacts immune response to subsequent pneumococcal conjugate vaccine in the elderly
Source: Eur Respir J 2005; 26: Suppl. 49, 673s
Year: 2005
Perception and uptake of the influenza and pneumococcal vaccinations in patients with COPD
Source: Annual Congress 2008 - Organisation of care and management of COPD
Year: 2008
Effectiveness of a 23-valent pneumococcal polysaccharide vaccine and a 13-valent pneumococcal conjugate vaccine among the elderly with chronic respiratory diseases
Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit
Year: 2018
Can the influenza vaccine response be predicted in COPD patients by clinical parameters?
Source: International Congress 2015 – Treatment and control of respiratory disease
Year: 2015
Comparison of efficacy of grippe vaccination and broncho vaxom administration in COPD patients
Source: International Congress 2015 – Different data in COPD
Year: 2015
Impact of influenza vaccination in patients with CAP
Source: Annual Congress 2009 - Aetiology and treatment of community-acquired pneumonia
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept